LifeStance Health Group, Inc. (LFST): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

LifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2026, Teresa DeLuca, M.D., notified the LifeStance Health Group, Inc. (the “Company”) board of directors (th

Original reporting
Published Oct 16, 2026, 9:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$LFST
Neutral
high confidence
Mentioned
$LFST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LFSTNeutralLow
01

Why it matters

The filing is a primary source disclosure; while material as a corporate action, the scale is modest and unlikely to move the stock significantly.

02

Market read

Provides a fresh corporate governance update; limited trading relevance beyond potential short‑term price pressure.

03

What to watch

Potential upcoming board appointments or strategic shifts not disclosed in the filing.

Relevance 6/10Novelty 5/10Timing: today

Background

LifeStance Health Group filed an 8‑K announcing a board member's resignation, a routine corporate governance update.

Company-level read

Ticker impact

$LFSTNeutralHigh confidence
Context

SEC Form 8‑K reports Dr. Teresa DeLuca's resignation from the board effective Dec 31, 2026.

Expected impact

likely slight pressure as the market prices the board change

Evidence & confidence

Direct filing indicates a primary disclosure; director exits typically have limited but negative impact on share sentiment.

Market effects

Minimal; governance change does not affect sector fundamentals.

None; company is US‑based with limited broader market effect.

Low; no global macro implications.

Counterpoint

The resignation could be seen as a positive sign if it clears the board for new strategic direction.

Key entities

  • LifeStance Health Group, Inc.

    Public mental health services provider (NASDAQ: LFST).

  • Teresa DeLuca, M.D.

    Resigning board member.

Related articles

$LFSTMed

BMO raises Lifestance Health stock price target on strong results

BMO Capital raised its price target on Lifestance Health (LFST) to $16.00, citing strong Q3 results. Revenue beat estimates by 5.6%, and EBITDA exceeded by 23.6%. The company raised its full-year outlook, but expects a sequential EBITDA decline due to reinvestment. LFST trades at $13.43 with a $5.1B market cap. The company also announced Q3 2026 earnings, surpassing expectations with a 25% revenue increase.

$LFSTMed

What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.

$LFSTMed

LifeStance Health Group Inc (LFST) (Q3 2026) Earnings Call Highlights: Revenue Jumps 25%

LifeStance Health (LFST) reported 25% revenue growth in Q3 2026. The company expects EHR implementation to reduce 2027 revenue growth by 1-2% and cost $20-30M. Clinician retention is stable, but new clinician retention is low. Q4 adjusted EBITDA guidance suggests a sequential decline due to planned investments. Specialty services, including Spravato, are growing but face variable payer reimbursement. Management remains optimistic about long-term margin expansion and clinician growth.

$LFSTHighAI 8/10

LifeStance (LFST) Q3 2026 Earnings Call Transcript

LifeStance (LFST) reported Q3 2026 revenue growth of 25% to $456M, driven by increased visit volumes and higher revenue per visit. The company expanded its clinician base by 11% and opened 8 new centers. It also raised full-year revenue guidance to $1.741B-$1.761B. LifeStance highlighted strong results in specialty services for treatment-resistant depression and plans to invest in strategic priorities. The company expects temporary revenue growth impact in 2027 due to EHR implementation.

$LFSTMed

LifeStance Health: Q3 Earnings Snapshot

LifeStance Health Group Inc. (LFST) reported Q3 net income of $22.4M, or 6 cents per share, beating estimates. Revenue was $455.9M, also exceeding forecasts. The company expects Q4 revenue of $446M-$466M and full-year revenue of $1.74B-$1.76B.